Episode
387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
- Podcast
- The Readout Loud
- Published
- Feb 5, 2026
- Duration seconds
- 1684
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/387-challenges-for-a-crucial-sickle-cell-treatment-and-the-latest-outlook-for-glp-1s/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-readout-loud-1134305/387-challenges-for-a-crucial-sickle-cell-treatment-and-the-latest-outlook-for-glp-1s.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment. It’s our pre-Super Bowl show, which triggered some co-host squabbling. Adam Feuerstein is all Patriots, Elaine Chen is Team Seahawks, while Allison DeAngelis, raised in Seattle but now a Boston denizen, struggles with dual loyalties. Our special guest this week is STAT reporter Jason Mast. And if you get a chance, wish Adam a happy birthday.